Isomiosamine
CAS 53844-46-5
MF C9H10N2 MW
146.19 g/mol
3-(3,4-dihydro-2H-pyrrol-2-yl)pyridine
rac-(3R)-3-(3,4-dihydro-2H-pyrrol-2-yl)pyridine
tumor necrosis factor alpha (TNFα) inhibitor, MyMD-1, MYMD-1, Isomyosamine, 3A50Y1J4LP, MyMD Pharmaceuticals
synthetic derivative of tobacco alkaloids
Isomyosamine, also known as MyMD-1 or MYMD-1, is a synthetic derivative of tobacco plant alkaloids being developed as a metabolic- and immunomodulator by MyMD Pharmaceuticals. To date, isomyosamine has been shown to suppress the production of IFN-γ, IL-2, IL-10, and TNF-α, and decrease the severity of experimental thyroiditis in a murine model.[1] Trials in humans are being planned, and some are underway, examining the potential benefits of isomyosamine in autoimmune diseases such as rheumatoid arthritis, and in sarcopenia and frailty.[2]
MyMD Pharmaceuticals claim that MYMD-1 is not immunosuppressive, and thus should not be associated with the dangerous side effects such as infections that are seen in currently used TNF-α inhibitors such as adalimumab.[3] While it is true that there currently is no evidence of immunosuppression in isomyosamine recipients, this has not yet been tested in large clinical trials
Safety and Efficacy of Isomyosamine in Reducing Inflammation and Treating Muscle Loss in Older Adults After Hip or Thigh Bone Fractures
CTID: NCT06942182
Phase: Phase 2
Status: Not yet recruiting
Date: 2025-04-24
SYN
Isomyosmine
[08] Isomyosmine (3-(3,4-dihydro-2H-pyrrol-2-yl)-pyridine) is a nicotine related alkaloid present in solanecea plants containing nicotine.
PAT
| Unless otherwise clear from context, all percentages referred to herein are expressed as percent by weight based on the total weight of the composition. Percentages expressed herein as “w/v” refer to mass, in grams, of the component per 100 ml of solvent. For example, a 1% (w/v) composition of isomyosmine contains lg (1000 mg) of isomyosmine per 100 ml of solvent, which is equivalent to 10 mg/ml. |
| Isomyosmine (3-(3,4-dihydro-2H-pyrrol-2-yl)-pyridine) is a nicotine related alkaloid present in solanecea plants containing nicotine. |
PAT
- Method of Treating Substance AddictionsPublication Number: US-2017333415-A1Priority Date: 2015-02-19
- Method of treating addictions to opioidsPublication Number: US-10471052-B2Priority Date: 2015-02-19Grant Date: 2019-11-12
- Method of treating cocaine addictionPublication Number: US-11331310-B2Priority Date: 2015-02-19Grant Date: 2022-05-17
- Method of treating disorders associated with chronic inflammationPublication Number: US-2021106578-A1Priority Date: 2015-03-31
- Method of Treating Substance AddictionsPublication Number: US-2020215045-A1Priority Date: 2015-02-19
- Compositions for e-cigarettesPublication Number: WO-2016133890-A1Priority Date: 2015-02-19
- Method of treating substance addictionsPublication Number: US-9884055-B2Priority Date: 2015-02-19Grant Date: 2018-02-06
- Method of Treating Substance AddictionsPublication Number: US-2018140590-A1Priority Date: 2015-02-19
- Methods of treating sarcopeniaPublication Number: US-11219620-B2Priority Date: 2015-03-31Grant Date: 2022-01-11
- Methods of Treating Apoptosis and Altering Programmed Cell DeathPublication Number: US-2018021321-A1Priority Date: 2015-03-31
- Methods of reversing normal aging process and extending lifespanPublication Number: US-11179382-B2Priority Date: 2015-03-31Grant Date: 2021-11-23
- Method of treating viral infectionsPublication Number: US-10786493-B2Priority Date: 2015-03-31Grant Date: 2020-09-29
- Methods of treating cancer, autoimmune disorders, and other conditions associated with chronic inflammationPublication Number: CN-107666907-BPriority Date: 2015-03-31Grant Date: 2022-05-13
AS ON OCT2025 4.511 LAKHS VIEWS ON BLOG WORLDREACH AVAILABLEFOR YOUR ADVERTISEMENT
join me on Linkedin
Anthony Melvin Crasto Ph.D – India | LinkedIn
join me on Researchgate
RESEARCHGATE
join me on Facebook
Anthony Melvin Crasto Dr. | Facebook
join me on twitter
Anthony Melvin Crasto Dr. | twitter
+919321316780 call whatsaapp
EMAIL. amcrasto@gmail.com
……
Scientific studies
Preclinical studies
One preliminary murine study comparing isomyosamine to rapamycin, the best-characterised drug slowing the progression of aging, reported an increase in lifespan in the isomyosamine cohort, indicating anti-aging activity. Isomyosamine’s anti-proliferative effects were similar to those of rapamycin.[4]
Clinical trials
A phase I randomised double-blind placebo-controlled trial on healthy volunteers examining the safety and pharmacokinetic properties of different amounts of isomyosamine found no serious adverse events, but 3 cases of mild dysgeusia in the highest-dose (600 mg) cohort. A preliminary decrease in TNF-α levels was reported in the lowest-dose (150 mg) cohort, but not in the placebo cohort.[5]
| Identifiers | |
|---|---|
| CAS Number | 53844-46-5 |
| 3D model (JSmol) | Interactive image |
| ChemSpider | 9461533 |
| PubChem CID | 11286546 |
| UNII | 3A50Y1J4LP |
| CompTox Dashboard (EPA) | DTXSID80461155 |
| InChI | |
| SMILES | |
| Properties | |
| Chemical formula | C9H10N2 |
| Molar mass | 146.193 g·mol−1 |
| Related compounds | |
| Related compounds | Myosmine Nicotine |
| Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).Infobox references | |
References
- Di Dalmazi, Giulia; Chalan, Paulina; Caturegli, Patrizio (2019-03-01). “MYMD-1, a Novel Immunometabolic Regulator, Ameliorates Autoimmune Thyroiditis via Suppression of Th1 Responses and TNF-α Release”. The Journal of Immunology. 202 (5): 1350–1362. doi:10.4049/jimmunol.1801238. ISSN 0022-1767. PMID 30674573. S2CID 59226562.
- “MyMD Pharmaceuticals® Provides Dosing Update on Phase 2 Multi-Center Clinical Trial of MYMD-1® as a Therapy for Delaying Aging and Extending Healthy Lifespan”. MyMD. Retrieved 2023-08-13.
- “MYMD-1®”. MyMD. Retrieved 2023-08-13.
- Sabini, Elena; O’Mahony, Alison; Caturegli, Patrizio (2023-02-24). Anderson, Rozalyn M (ed.). “MyMD-1 Improves Health Span and Prolongs Life Span in Old Mice: A Noninferiority Study to Rapamycin”. The Journals of Gerontology: Series A. 78 (2): 227–235. doi:10.1093/gerona/glac142. ISSN 1079-5006. PMID 35914953.
- Brager, Jenna; Chapman, Chris; Dunn, Leonard; Kaplin, Adam (2022-11-11). “A Double-blind, Placebo-controlled, Randomized, Single Ascending, and Multiple Dose Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral Dose Isomyosamine Capsules in Healthy Adult Subjects”. Drug Research. 73 (2): 95–104. doi:10.1055/a-1962-6834. ISSN 2194-9379. PMC 9902179. PMID 36368677.
/////////////isomiosamine, tumor necrosis factor alpha (TNFα) inhibitor, MyMD-1, MYMD-1, Isomyosamine, 3A50Y1J4LP, MyMD Pharmaceuticals, ANAX, ADVECT, BLUE JET
ADVERTISEMENT
ANAX LABORATORIES, WEBSITE https://www.anaxlab.com/
Discovery Solutions, Supporting the chemistry needs of clients in the Medical, Analytical and Bio Sciences
Development Solutions, Developing from Lab scale to PR&D, Kilo Scale-ups and Commercial Scales
SEE MORE………Integrated Solutions, Manufacturing Solutions, Products,
Can’t Find? Let’s Connect
Phone : +91 897704 2010 / +91 9177075735, Email : info@anaxlab.com
ADVERTISEMENT
Advect Process Systems Ltd. https://advectprocess.com/
ADVECT PROCESS SYSTEMS CANADA LTD
51 Beechwood Rd., Cambridge, ON Canada N1S 3S1, Call Now +1 306 850 6737, Mail Now, ask@advectprocess.com
ADVERTISEMENT
BLUE JET HEALTHCARE LTD, https://bluejethealthcare.com
Looking for a Reliable SNAC Manufacturer? Let’s Talk.
At Blue Jet Healthcare Ltd, we specialize in the scalable, high-purity production of SNAC—a critical excipient powering the next generation of oral peptide therapeutics.
With increasing demand for SNAC across global pharma pipelines, choosing the right manufacturing partner is essential. Quality, timelines, and consistency matter.
Phone No. +91 (22) 22075307 / +91 (22) 22071691
Business Development/ Contract Manufacturing: marketing1@bluejethealthcare.com, madhu.gautam71@gmail.com